Viridian Therapeutics just broke Amgen's six-year stranglehold on thyroid eye disease with the FDA approval of Lumvoa, the first competitor to the $1.9 billion Tepezza franchise. The label is broader, the treatment is shorter, and Wall Street thinks the stock has 80% upside if the launch delivers.
For six years, patients with thyroid eye disease had exactly one option. One drug. One company. One price. Take it or leave it.
That era just ended.
In June 2026, the FDA approved Lumvoa (veligrotug-vvze) from Viridian Therapeutics, making it only the second drug ever cleared to treat thyroid eye disease (TED), a painful autoimmune condition that causes the eyes to bulge, swell, and sometimes lose vision. Viridian's stock jumped about 6% on the news, but the bigger story isn't the ticker. It's what this means for a market that Amgen's Tepezza has owned entirely since 2020.
Tepezza pulled in $1.9 billion in 2024 alone. Now it has to share.
What Thyroid Eye Disease Actually Does to People
Imagine your immune system deciding your eye sockets are the enemy. That's TED in a nutshell. The condition affects roughly 90 to 155 out of every 100,000 people, depending on the study, and it shows up most often in patients with Graves' disease. About 25–50% of Graves' patients develop it.
The disease inflames the tissue behind and around the eyes, pushing them forward (a symptom called proptosis), causing double vision (diplopia), chronic pain, and in severe cases, damage to the optic nerve. Around 18% of TED patients in one large U.S. registry had vision-threatening complications.
Beyond the medical toll, the disfigurement carries a brutal psychosocial burden: depression, anxiety, social isolation. For years, the standard treatment was high-dose IV steroids, orbital radiation, or multiple reconstructive surgeries, none of which addressed the root cause. When Tepezza arrived as the first targeted therapy, it was a genuine breakthrough.
But breakthroughs can get comfortable when nobody's competing with them.
One Drug, Lots of Problems
Tepezza works. Nobody disputes that. It blocks IGF-1R (insulin-like growth factor-1 receptor), a protein that drives the inflammatory cascade behind TED. Clinical trials showed meaningful reductions in eye bulging and double vision.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
But Tepezza also comes with baggage. The drug requires eight IV infusions over about 24 weeks, which means repeated trips to an infusion center, time off work, and logistical headaches. Safety concerns include hearing impairment (sometimes permanent), elevated blood sugar, and infusion reactions. And then there's the cost: Tepezza is one of the most expensive specialty drugs on the market, with access barriers that hit underserved populations hardest.
Perhaps the biggest limitation? Tepezza was studied primarily in active, moderate-to-severe TED. Patients with chronic, "burned-out" disease who still had disfigurement and double vision were largely left without a targeted option.
That's the gap Viridian drove straight through.
Lumvoa's Label Is the Real Story
The FDA approved Lumvoa for thyroid eye disease regardless of disease activity or duration. Read that again. It covers both active and chronic TED, making it the first approved therapy with labeling that spans both populations.
This is a bigger deal than it sounds. Think of it like a flu drug that works whether you're on day two of symptoms or day twelve. Tepezza's clinical story is rooted in active disease. Lumvoa's label explicitly includes the chronic patients that Tepezza's data didn't fully address.
The dosing is also slightly leaner: five IV infusions over 12 weeks, compared to Tepezza's eight infusions over roughly 24 weeks. Fewer infusions, shorter treatment course.
The Data That Got It Done
Viridian ran two pivotal Phase 3 trials, THRIVE (active TED) and THRIVE-2 (chronic TED), and both delivered.
In THRIVE, 70% of patients on Lumvoa achieved a meaningful reduction in eye bulging, versus just 6% on placebo. That's not a marginal win; that's a blowout. 49% of patients saw their double vision completely resolve.
In THRIVE-2, the chronic TED trial, 56% of treated patients hit the eye-bulging endpoint compared to 8% on placebo. Double vision improved too, with a 56% response rate versus 25% for placebo.
The mechanism is similar to Tepezza (both target IGF-1R), but Viridian claims a key pharmacologic difference. In lab studies, Lumvoa acts as a "full antagonist," nearly completely blocking the IGF-1 signal at therapeutic concentrations. Tepezza, by contrast, showed only partial blockade in the same head-to-head experiments. Whether that translates into meaningful clinical superiority is still an open question, but the preclinical data give Viridian a compelling talking point.
Wall Street's Reaction: Enthusiastic but Patient
The stock popped about 6% after hours, a positive but hardly euphoric response. The reason? The approval was widely expected after strong trial data and a Priority Review designation from the FDA. The market had already priced in a good chunk of the upside.
Still, analysts see significant room to run. Sixteen out of 17 analysts rate VRDN a Buy or better, with an average 12-month price target around $35 to $36 per share. The stock was trading in the high teens at the time of approval, implying roughly 80–90% upside if the launch goes well.
RBC Capital raised its target to $35, citing trial data that exceeded expectations. Citizens reiterated a $35 target. H.C. Wainwright kept a Buy rating with a $22 target, noting the stock looked undervalued.
The consensus view: regulatory risk is gone, but execution risk is very much alive. Viridian is transitioning from a development-stage company to a commercial one, and launching a specialty drug against an entrenched $1.9 billion incumbent is no small task. Analysts flagged spending discipline, payer coverage, and potential equity dilution as the variables to watch.
The Bigger Picture: Why Competition Matters Here
Tepezza's monopoly wasn't just a business story. It was a patient-access story. When one company controls the only treatment for a serious disease, pricing power is unchecked, and patients who can't navigate insurance hurdles or reach infusion centers are left behind.
Lumvoa doesn't solve all of that overnight. It's still an IV infusion, still a specialty drug, and Viridian hasn't publicly disclosed its pricing. But competition is the single most reliable force for improving access in specialty pharma. Two drugs on the market means payer leverage, formulary negotiations, and options for patients who couldn't tolerate or access Tepezza.
Viridian isn't stopping here, either. The company has a subcutaneous version called elegrobart (a self-injectable, longer-acting IGF-1R antibody) in Phase 3 trials, with a BLA submission expected in Q1 2027. If approved, that would give patients three choices: Tepezza, Lumvoa IV, or a shot they could potentially take at home every four to eight weeks.
For a disease that had zero targeted treatments seven years ago, three options would be remarkable.
The Bottom Line
Viridian just became a commercial-stage biotech company, Amgen just got its first real competitor in a nearly $2 billion market, and TED patients just got something they haven't had before: a choice. The approval is the easy part. The launch is where the real story begins.
4 min read
One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie's $18B Drug
A tiny biotech called Oruka just posted psoriasis clearance rates that numerically beat AbbVie's $17.6 billion juggernaut Skyrizi, and it might only need one shot a year. Wall Street is losing its mind.
